Structure, function, and inhibition of drug reactivating human gut microbial β-glucuronidases

Kristen A. Biernat¹, Samuel J. Pellock¹, Aadra P. Bhatt², Marissa M. Bivins¹, William G. Walton³, Bich Ngoc T. Tran³, Lianjie Wei¹, Michael C. Snider¹, Andrew P. Cesmat¹, Ashutosh Tripathy⁴, Dorothy A. Erie¹ & Matthew R. Redinbo³,⁴,⁵

Bacterial β-glucuronidase (GUS) enzymes cause drug toxicity by reversing Phase II glucuronidation in the gastrointestinal tract. While many human gut microbial GUS enzymes have been examined with model glucuronide substrates like p-nitrophenol-β-D-glucuronide (pNPG), the GUS orthologs that are most efficient at processing drug-glucuronides remain unclear. Here we present the crystal structures of GUS enzymes from human gut commensals Lactobacillus rhamnosus, Ruminococcus gnavus, and Faecalibacterium prausnitzii that possess an active site loop (Loop 1; L1) analogous to that found in E. coli GUS, which processes drug substrates. We also resolve the structure of the No Loop GUS from Bacteroides dorei. We then compare the pNPG and diclofenac glucuronide processing abilities of a panel of twelve structurally diverse GUS proteins, and find that the new L1 GUS enzymes presented here process small glucuronide substrates inefficiently compared to previously characterized L1 GUS enzymes like E. coli GUS. We further demonstrate that our GUS inhibitors, which are effective against some L1 enzymes, are not potent towards all. Our findings pinpoint active site structural features necessary for the processing of drug-glucuronide substrates and the inhibition of such processing.

The gastrointestinal (GI) microbiome harbours incredible metabolic potential and is intimately connected to human physiology. Possessing 150 times more genes than are found in the human genome, the gut microbiome encodes a vast number of enzymes that function in a variety of metabolic pathways, including the biosynthesis of essential vitamins and the breakdown of complex, non-digestible polysaccharides¹–⁴. The gut microbiota has been termed both a “metabolic organ” and an “essential organ”, and it possesses a metabolic capacity that rivals that of the liver, which is critical to both anabolism and catabolism in the human host⁵,⁶.

Like the liver, the gut microbiota are capable of transforming xenobiotics such as pharmaceuticals, environmental pollutants, and dietary compounds ingested by humans⁷. However, the types of reactions performed by gut microbial enzymes are distinct from those performed by host liver enzymes. Drug metabolism enzymes in the liver transform relatively non-polar xenobiotics of low-molecular weight into molecules that are more polar and of a higher molecular weight, facilitating their excretion from the body⁸. Specifically, these reactions are carried out by Phase I enzymes, which introduce hydroxyl, thiol, and amine functional groups to the xenobiotic scaffold, and Phase II enzymes, which transfer glucuronide, sulphate, and glutathione moieties onto the Phase I functional groups or the xenobiotic scaffold⁹,¹⁰. In contrast, GI microbial enzymes perform hydrolytic and reductive transformations that are capable of reversing the Phase I and Phase II reactions performed by liver enzymes⁹. For this reason, the transformations carried out by microbial enzymes can drastically alter the pharmacological properties of xenobiotics.

Bacterial β-glucuronidase (GUS) proteins comprise one class of gut microbial enzymes that have been shown to reverse Phase II glucuronidation and, in doing so, cause the GI toxicity of several drugs¹¹. This process has been extensively studied in connection with the colorectal and pancreatic cancer drug irinotecan and its active...
and toxic metabolite, SN-38\textsuperscript{12,13}. Prior to excretion, SN-38 is sent to the liver where uridine diphosphate glucuronosyltransferase (UGT) enzymes attach a glucuronide group to the SN-38 scaffold, converting it to the inactive metabolite SN-38-glucuronide (SN-38-G), which is non-toxic. However, upon its delivery to the GI tract, gut microbial GUS enzymes hydrolyse SN-38-G and reactivate it back into its toxic form SN-38, which causes dose limiting diarrhoea\textsuperscript{14,15}. In a similar fashion, NSAIDs have also been shown to cause small intestinal ulcers and inflammation, presumably due to the action of GUS enzymes that convert NSAID glucuronides back into their parent forms following Phase II glucuronidation\textsuperscript{16}. In previous work, we have shown in mice that inhibitors selective for bacterial GUS alleviated SN-38 dose limiting diarrhoea and reduced the number of NSAID-induced small intestinal ulcers, further suggesting that GUS enzymes give rise to undesired GI side effects by reversing Phase II glucuronidation\textsuperscript{17–19}.

It is apparent that GUS enzymes are capable of hydrolysing a diverse array of glucuronides, but limited information is available on the specific types of GUS enzymes that are most efficient at processing drug glucuronides. In an attempt to gain insight into the structural and functional diversity of GUS enzymes, we recently reported an atlas of 279 unique GUS enzymes identified from the stool sample catalogue in the Human Microbiome Project (HMP) that clustered into six structural groups based on their active site loops, Loop 1 (L1), Mini Loop 1 (mL1), Loop 2 (L2), Mini Loop 2 (mL2), Mini Loop 1,2 (mL1,2), and No Loop (NL)\textsuperscript{20} (Fig. 1a–c). We further showed that representative GUS enzymes possessing a Loop 1 were capable of processing the small standard glucuronide substrate p-nitrophenol-β-D-glucuronide (pNPG) faster than non-L1 GUS enzymes\textsuperscript{20}. We also found that two selective microbial GUS inhibitors, Inhibitor 1 and UNC10201652, were potent against the L1 \textit{E. coli} GUS (EcGUS) but did not inhibit the non-L1 GUS enzyme mL1 \textit{Bacteroides fragilis} GUS (BfGUS)\textsuperscript{17,21}. From these data, we hypothesized that GUS enzymes possessing a Loop 1 efficiently process drug glucuronides, such as SN-38-G and NSAID glucuronides, and are susceptible to inhibition by our GUS selective inhibitors.

To date, five L1 GUS enzymes, EcGUS, \textit{Eubacterium eligens} GUS (EcGUS), \textit{Streptococcus agalactiae} (SaGUS), \textit{Clostridium perfringens} GUS (CpGUS), and \textit{Faecalibacterium prausnitzii} (FpGUS) have exhibited activity with pNPG, and all have been structurally characterized, with the exception of FpGUS\textsuperscript{17,20,21}. All four L1 GUS structures exhibited similar tertiary, quaternary, and active site architectures\textsuperscript{17,21,22}. To determine whether any structural and functional differences exist among L1 GUS enzymes and to test our hypothesis that GUS enzymes containing a Loop 1 are the most efficient within the GUS family at processing drug glucuronides, we
cloned, expressed, and purified two additional L1 GUS enzymes, *Lactobacillus rhamnosus* GUS (LrGUS) and *Ruminococcus gravis* GUS (RgGUS). *Lactobacillus rhamnosus* was found to be adherent to healthy colon tissue in a patient biopsy obtained at UNC Hospitals (T. Keku, personal communication); thus, we chose to study a GUS from this bacterial species. *Ruminococcus gravis* GUS was previously identified and examined for general biochemical properties.

Here we present the crystal structures of the L1 GUS enzymes *Fp*GUS, *Lr*GUS, and *Rg*GUS, as well as the NL *Bacteroides dorei* (BdGUS), and show that *Lr*GUS and *Rg*GUS exhibit unique active site features not previously seen in L1 GUS enzymes. We also determined the kinetic parameters $k_{\text{cat}}$ and $K_m$ for each L1 GUS enzyme and our panel of non-L1 GUS enzymes with the small standard substrate pNPG. Surprisingly, we found that *Fp*GUS, *Lr*GUS, and *Rg*GUS exhibited catalytic efficiencies 10 to 100-fold lower than the those of the L1 GUS enzymes previously characterized. We further demonstrate that while these three L1 GUS enzymes were not inhibited by our selective GUS inhibitors, NL BdGUS was weakly inhibited, despite its lack of a Loop 1. We show that our panel of GUS enzymes differentially processed the NSAID metabolite diclofenac glucuronide (DCF-G) and that the relative cleavage rates were analogous to that observed for pNPG. Finally, we demonstrate that treating mice with diclofenac (DCF) increases GUS activity in faecal samples. These findings advance our understanding of the structure, function and inhibition of GUS enzymes. Furthermore, they suggest that the specific amino acid composition of Loop 1, as well as additional GUS structural features, likely play a role in the ability of GUS enzymes to cleave drug-glucuronides and in the efficacy of bacterial GUS inhibitors.

**Results**

**Visualization of structure-function relationships across GUS proteins.** Human gut microbial GUS enzymes have been previously shown to exhibit unique structures and functions\(^{20}\). To gain greater insight into the specific sequence-structure-function relationships among GUS proteins, particularly those belonging to the L1 class, we generated a sequence similarity network (SSN), which groups protein sequences into clusters and facilitates the analysis of functional relationships within protein families.\(^{24}\) We utilized the 279 GUS protein sequences identified in the Human Microbiome Project (HMP) database to construct the SSN, as well as the sequences of the L1 GUS enzymes previously characterized (*Ec*GUS, *Ec*GUS, *Fp*GUS, *Cp*GUS, and *Sa*GUS), and the new L1 GUS sequences *Rg*GUS and *Lr*GUS.\(^{20,21}\)

The GUS enzymes examined largely clustered based on their previously defined active site loop architectures: L1, mL1, l1, l2, mL2, mL1,2, and NL (Fig. 1). Of the GUS enzymes that have already been examined both structurally and functionally, and are annotated on the SSN, we found that the non-L1 GUS enzymes, mL1 B/GUS, L2 Bacteroides uniformis (BuGUS), nl. BdGUS, mL1,2 Bacteroides ovatus (BoGUS), and L2 Parabacteroides merdae (PmGUS), clustered with GUS enzymes containing their same loop type (Fig. 1c). Three of the previously characterized L1 GUS enzymes, *Ec*GUS, *Sa*GUS, and CpGUS, were singletons that did not group with any other GUS enzyme, while *Ee*GUS clustered with two other GUS enzymes from bacteria identified as *Eubacterium sp.* *Fp*GUS clustered with the new L1 *Rg*GUS and three other L1 GUS enzymes in a group we have termed as the “L1 Cluster” (Fig. 1c). One of the five GUS enzymes that compose the L1 Cluster was identified as a GUS from *Faealibacterium prausnitzii* that shares 79% sequence identity to the previously characterized *Fp*GUS sequence.\(^{20}\) The remaining GUS sequences that associated within the L1 Cluster were determined to belong to bacteria that could not currently be identified. Finally, the new L1 *Lr*GUS was a singleton and did not group with any other GUS enzyme.

To test our previous hypothesis that, among GUS family members, L1 GUS enzymes most efficiently process small glucuronide substrates, we cloned, expressed and purified two previously uncharacterized L1 GUS enzymes, *Rg*GUS and *Lr*GUS, for subsequent structural and functional studies. These two novel GUS enzymes, along with the ten GUS enzymes previously characterized, compose the panel of GUS enzymes examined below.

**Structural analysis.** The structures of the L1 GUS enzymes *Ec*GUS (PDB: 6BJW), *Sa*GUS (PDB: 4JKL), *Cp*GUS (PDB: 4JKM), and *Ec*GUS (PDB: 3LPG) have been previously determined. To further examine the structural variability of L1 GUS enzymes, we determined the crystal structures of *Fp*GUS, *Lr*GUS, and *Rg*GUS (Fig. 2 and Table S1). The structures of these three new enzymes reveal highly similar tertiary structures (Fig. 2a) relative to one another, as well as to the previously determined L1 GUS enzymes (Fig. S1).\(^{20,21}\) *Fp*GUS, *Lr*GUS, and *Rg*GUS share a similar core fold with *Ec*GUS, with 1.7 Å root-mean-square deviation (rmsd), 1.7 Å rmsd, and 2.0 Å rmsd, respectively, over 576 Cα equivalent positions. The three new L1 GUS enzymes also retain the same tetramer organization compared to previously determined L1 structures, in which GUS monomers are in a “C-term-mediated” tetrameric state rather than a “square” tetrameric state, as exhibited by mL1 B/GUS (PDB: 3CMG) and discussed below (Figs 2b and S2).\(^{21}\)

While *Lr*GUS, *Rg*GUS, and *Fp*GUS also exhibit similar tertiary and quaternary structures when compared to previously determined L1 GUS enzymes, *Lr*GUS and *Rg*GUS display unique features within their active sites. Specifically, *Lr*GUS possesses a patch of negatively charged residues, E450, D451, and D452, which we term the “EDD” motif (Figs 2c and S3a). These positions are generally occupied by polar or hydrophobic residues in our previously characterized L1 GUS enzymes, such as M453, T454, and S455 at the equivalent positions in *Fp*GUS, for example (Figs 2c and S3b). In the *Rg*GUS active site, six amino acids from the Loop 1 region of this enzyme were observed to adopt an alpha helix conformation that directly folds over the catalytic gorge (Fig. 2c). This structure represents the first instance in which Loop 1 adopts a secondary structural motif. Together, these data extend our knowledge regarding the active site structural variability sampled by human gut microbial GUS enzymes.

To further advance our understanding of GUS structure and function we also determined the crystal structure of NL BdGUS (Fig. 3 and Table S1). Like the L1 GUS structures, BdGUS shares a similar core fold with *Ec*GUS, with 3.1 Å root-mean-square deviation (rmsd) over 528 Cα positions (Figs 3a and S1). Unlike the L1
GUS enzymes, BdGUS is a dimer and possesses two additional domains at its C-terminus (Figs 3a and S2). Sequence analysis revealed that first C-terminal domain of BdGUS is a “domain of unknown function” (DUF). The second C-terminal domain of BdGUS is a member of the carbohydrate binding module (CBM) 57 family, based on malectin25. The presence of these C-terminal domains likely explains the unique quaternary arrangement of BdGUS compared to that of other L1 GUS enzymes.

The tertiary and quaternary structure in BdGUS is highly similar to that exhibited by BuGUS, with a 2.3 Å root-mean-square deviation over 816 C\(_\alpha\) positions (Fig. S4). Both contain one DUF and one CBM, and their dimers are arranged in identical configurations29. While BdGUS does not possess a loop at the active site, as
predicted by sequence analysis, it does contain a loop insert in the CBM that enters the active site and is not present in BuGUS (Figs 3b and S4). Taken together, these structural data reveal new variability in active site features for the L1 GUS enzymes and a new understanding of the types of quaternary structures and active sites sampled by non-L1 GUS proteins.

### pNPG processing

L1 GUS enzymes have been previously shown to process the small standard substrate pNPG faster than non-L1 GUS enzymes. To gain greater insight into the small molecule glucuronide processing capabilities of L1 GUS enzymes, we assessed the ability of LrgGUS and RrgGUS, which have not been previously characterized, to cleave pNPG by determining their $k_{cat}$ and $K_m$ at their optimal pH values. We determined the optimal pH values of LrgGUS and RrgGUS to be 4.5 and 6.5, respectively (Fig. S5). While pNPG hydrolysis by the remaining ten GUS enzymes in our panel have been previously assessed, these data represent either apparent $k_{cat}$ values or $k_{cat}/K_m$ values determined at non-optimal pHs. Therefore, we used the Michaelis-Menten equation to determine the $k_{cat}$ and $K_m$ values at the optimal pH of the remaining GUS enzymes analysed to generate a complete set of kinetic parameters suitable for comparison (Table 1 and Figs S5, S6, and S7). RrgGUS and BuGUS exhibited complex substrate inhibition kinetics, and we were not able to fit these to established substrate inhibition models (Fig. S8). Consequently, apparent $k_{cat}$ and $K_m$ values were estimated at low pNPG concentrations at which inhibition was not observed (Figs S6 and S7). Future studies will explore the mechanistic and structural properties of this inhibition.

The L1 GUS enzymes EcGUS, EeGUS, and SaGUS exhibited the highest turnover numbers (~120 s\(^{-1}\)) and are the most efficient of the twelve GUS enzymes at processing pNPG, with catalytic efficiencies ranging from 540 to 920 s\(^{-1}\)mM\(^{-1}\). The L1 GUS enzymes CpGUS and FpGUS demonstrated moderate pNPG processing rates, exhibiting $k_{cat}$ values of 57 s\(^{-1}\) and 58 s\(^{-1}\), respectively. However, FpGUS exhibited the second highest $K_m$ (2.2 mM) of all the GUS enzymes tested, resulting in a lower catalytic efficiency compared to that of EcGUS, EeGUS, SaGUS, and CpGUS. In addition, while FpGUS was previously concluded to process pNPG faster than the non-L1 GUS enzymes BfGUS and BuGUS, determination of $k_{cat}$ and $K_m$ values reveal that FpGUS demonstrates a lower catalytic efficiency than these two GUS enzymes. Interestingly, the L1 GUS enzymes LrgGUS and RrgGUS exhibited much lower $K_m$ values (10.0 s\(^{-1}\) and 2.8 s\(^{-1}\), respectively) than the five other L1 GUS enzymes as well as Km values ~10-fold higher than that of EcGUS. LrgGUS and RrgGUS also demonstrated lower catalytic efficiencies than those of BfGUS and BuGUS, which are mL1 and mL2 GUS enzymes, respectively. These results for LrgGUS and RrgGUS likely reflect their unique active site features, appearing to be electrostatically and sterically occluded from processing this small molecule glucuronide substrate.

PmGUS and BoGUS, which are mL2 and mL1,2 GUS enzymes, respectively, are even poorer than LrgGUS and RrgGUS in utilizing this substrate, exhibiting the lowest pNPG processing efficiencies observed, with $k_{cat}/K_m$ values of 3–4 orders of magnitude less than that of EcGUS. The mL2 PmGUS processed pNPG the slowest, with a $k_{cat}$ value of 0.088 s\(^{-1}\) and exhibited the highest $K_m$ value (2.0 mM). Thus, gut microbial GUS enzymes offer a range of active site architectures and activities toward a model small glucuronide substrate, likely reflecting the range of variable native substrates they likely evolved to process within the GI tract.

### GUS inhibition

Structural evidence suggests that the loop present in L1 GUS enzymes makes contacts with Inhibitor 1 and UNC10201652, stabilizing it within the active site. We sought to assess the inhibition properties of these inhibitors against both the L1 GUS and non-L1 GUS enzymes within our panel. To date, our inhibitors have only been tested with pNPG at pH 7.4. However, the gut pH increases from approximately 5 in the proximal duodenum to about 7.4 in the colon. Thus, we determined IC\(_{50}\) values for Inhibitor 1 and UNC10201652 against each GUS at pH 6.5 and 7.5 to sample two pH values in the GI tract (Figs S9 and S10).

We first tested whether we observed inhibition at 100 mM Inhibitor 1 or UNC10201652 at pH 6.5 and 7.5 for each GUS enzyme. However, due to their poor pNPG processing activity, exhibiting $k_{cat}$ values of less than 1.
1 s$^{-1}$, PmGUS and BoGUS were not amenable for analysis. With the remaining ten enzymes, if 80% or greater inhibition was observed, an IC$_{50}$ was determined. The L1 GUS enzymes EcGUS and SaGUS were inhibited by 80% or greater by 100 µM of Inhibitor 1 (Fig. S10a,b), while the remaining L1 GUS enzymes and the non-L1 GUS enzymes did not appear to be inhibited by 80% at 100 µM. Inhibitor 1 was most potent against EcGUS and exhibited an IC$_{50}$ value of $\approx$2 µM at both pH 6.5 and 7.5 (Table 2 and Fig. S10a,b). For SaGUS, Inhibitor 1 demonstrated an IC$_{50}$ value of $>25$ µM (Fig. S10a,b). The potency of Inhibitor 1 did not appear to be affected by pH for either EcGUS or SaGUS (Table 2 and Fig. S10a,b).

At 100 µM UNCI0201652, the L1 GUS enzymes EcGUS, EcGUS, SaGUS, and CpGUS were inhibited at both pH 6.5 and 7.5 (Fig. S10c). In contrast, FpGUS and BdGUS were inhibited at pH 7.5 but did not show an inhibition of 80% or greater at pH 6.5 (Fig. S10c,d). UNCI0201652 was most potent against CpGUS with an IC$_{50}$ value of 26 nM at pH 7.5 and demonstrated nanomolar IC$_{50}$ values for EcGUS and SaGUS at pH 7.5 (100 nM and 133 nM, respectively) (Table 2). Of all the L1 GUS enzymes tested, UNCI0201652 was least potent towards FpGUS, with a predicted IC$_{50}$ value of $>3$ µM at pH 7.5 (Fig. S10c). Unlike Inhibitor 1, the potency of UNCI0201652 decreased with decreasing pH for all enzymes tested (Table 2). The decrease in UNCI0201652 potency appeared to vary with each enzyme tested. For EcGUS, the potency decreased by 3-fold from pH 7.5 to pH 6.5, whereas the potency decreased by 6-fold for CpGUS as the pH dropped from 7.5 to 6.5. Finally, despite its lack of an active site loop, the NL BdGUS was found to be weakly inhibited at pH 7.5 by UNCI0201652, with a predicted IC$_{50}$ value of $>25$ µM (Fig. S10c). Thus, this compound appears to be capable of associating with gut microbial GUS enzymes via contacts not exclusively limited to Loop 1-mediated interactions.

### DCF-G processing.

While pNPG serves as a useful tool to assess the glucuronide processing capabilities of GUS enzymes, it is not a substrate present in the GI tract. Given our hypothesis that L1 GUS enzymes efficiently process drug glucuronides, we determined using ultra performance liquid chromatography (UPLC) the cleavage rates of the novel L1 GUS enzymes FpGUS, LrGUS, RgGUS, as well as the ten additional enzymes in our GUS panel, with the physiologically relevant glucuronide metabolite of the NSAID diclofenac, DCF-G (Table 3 and Fig. S11).

Analogous to their pNPG processing rates, LrGUS and RgGUS were the slowest L1 GUS enzymes to hydrolyse DCF-G and exhibited apparent k$_{\text{cat}}$ values of 10 s$^{-1}$ and 24.0 s$^{-1}$, respectively, at a substrate concentration of 400 µM. In comparison, EcGUS and SaGUS hydrolysed DCF-G the fastest with an apparent k$_{\text{cat}}$ of 138 s$^{-1}$ and 97 s$^{-1}$, respectively. EcGUS, one of the three fastest GUS enzymes to process pNPG, cleaved DCF-G faster than LrGUS and RgGUS but slower than the other L1 GUS enzymes, exhibiting a k$_{\text{cat}}$ of 30.7 s$^{-1}$.

The non-L1 GUS enzymes processed DCF-G slower than all of the L1 GUS enzymes tested, with the exception of BfGUS, which cleaved DCF-G at a rate of 15.1 s$^{-1}$, and BoGUS, which cleaved DCF-G at a rate equal to that of LrGUS. PmGUS processed DCF-G the slowest of all of the GUS enzymes tested, exhibiting the apparent k$_{\text{cat}}$ value of 0.03 s$^{-1}$. Taken together, these data demonstrate that overall trends with small molecule glucuronide substrates are maintained when comparing pNPG and DCF-G and suggest that L1 GUS enzymes catalyse the hydrolysis of small molecule glucuronides more efficiently than other classes of GUS enzymes. Specifically, these data highlight the fact that EcGUS, CpGUS and SaGUS efficiently reactivated the inactive NSAID metabolite diclofenac-glucuronide back to the active and GI-toxic NSAID diclofenac, and are effectively inhibited by UNCI0201652. Thus, not all L1 GUS enzymes process this small molecule drug glucuronide well, but those that do are inhibited in vitro by UNCI0201652.

### Glucuronide processing by faecal extracts.

The data presented above show that pNPG and DCF-G are processed by gut microbial GUS enzymes in vitro. To examine whether the GUS enzymes are also able to cleave a small glucuronide substrate in vivo, we incubated pNPG with the faecal extracts collected from four adult mice. pNPG processing was observed in all faecal samples, suggesting that the mouse intestine harbours GUS enzymes.

---

**Table 2.** Potency of Inhibitors Toward a Range of Gut Microbial GUS Enzymes. Uncertainties for IC$_{50}$ values in nM are presented as the average of 3 biological replicates and errors are SEM. ND means not determined because no inhibition was observed up to 100 µM. NM means not measured because these enzymes showed k$_{\text{cat}}$ values for pNPG cleavage of less than 1 sec$^{-1}$.

| Loop | Class | GUS | Inhibitor 1 (IC$_{50}$ nM) | UNCI10201652 (IC$_{50}$ nM) |
|------|-------|-----|--------------------------|-----------------------------|
|      |       |     | pH 6.5 | pH 7.5 | pH 6.5 | pH 7.5 |
| L1   | E. coli | 2000 ± 200 | 1900 ± 100 | 310 ± 20 | 100 ± 8 |
| L1   | E. elegans | ND | ND | 1900 ± 100 | 410 ± 30 |
| L1   | S. agalactiae | >25000 | >25000 | 450 ± 30 | 133 ± 3 |
| L1   | C. perfringens | ND | ND | 160 ± 10 | 26 ± 3 |
| L1   | R. rhamnosus | ND | ND | ND | ND |
| L1   | R. gnarus | ND | ND | ND | ND |
| ml1  | B. fragilis | ND | ND | ND | ND |
| ml2  | B. uniformis | ND | ND | ND | ND |
| ml1,2| P. merdae | NM | NM | NM | NM |
| NL   | B. ovariatus | ND | ND | ND | >25000 |
Table 3. Apparent kₐₑₙ for Various GUS Enzymes with DCF-G. Data are presented as the average of 3 biological replicates and errors are SEM.

| Loop Class | GUS          | Optimal pH | Apparent kₐₑₙ (s⁻¹) |
|------------|--------------|------------|---------------------|
| L1         | E. coli      | 7.4        | 30.7 ± 0.7          |
| L1         | E. eligens   | 6.5        | 138 ± 2             |
| L1         | S. agalactiae| 6.5        | 97 ± 5              |
| L1         | C. perfringens| 6.5      | 61.5 ± 0.6          |
| L1         | F. prausnitzii| 6.0      | 32 ± 3              |
| L1         | L. rhamnosus | 4.5        | 10 ± 1              |
| L1         | B. gnavus    | 6.5        | 24.0 ± 0.5          |
| mL1        | B. fragilis  | 5.0        | 15.1 ± 0.5          |
| L2         | B. uniformis | 5.5        | 10 ± 1              |
| mL2        | P. mordae    | 5.5        | 0.034 ± 0.001       |
| mL1,2      | B. ovatus    | 5.0        | 1.64 ± 0.04         |
| NL         | B. dorei     | 6.0        | 9.8 ± 0.6           |

Discussion
L1 GUS distribution across the SSN points to distinct substrate specificities. We previously demonstrated that a small set of L1 GUS enzymes are capable of processing small glucuronide substrates and are susceptible to selective GUS inhibition, while non-L1 GUS enzymes process larger glucuronide-containing substrates and are not effectively inhibited. Here, we extend these investigations by examining the structure and function of two novel L1 GUS enzymes, as well as a panel of ten additional L1 and non-L1 GUS enzymes. By creating an SSN using the 279 GUS enzymes identified from the HMP, we found that while L1 GUS enzymes characterized in this paper retained highly similar tertiary and quaternary structures to previously characterized GUS enzymes, they do not cluster together (Fig. 1c). Further, EcGUS, SaGUS, CpGUS, and LrGUS did not cluster with any other L1 or non-L1 GUS enzyme. Given the fact that these L1 GUS enzymes displayed a range of DCF-G and pNPG cleavage rates, the separation of L1 GUS enzymes across the SSN may indicate that they possess distinct substrate specificities. These observations demonstrate the utility of SSNs to predict functional characteristics within large enzyme families encoded by the gut microbiome.

Active site loop architecture is important in the efficient processing of small glucuronide substrates. To explain the range of catalytic efficiencies exhibited by our panel of GUS enzymes, particularly the poor processing activity demonstrated by the new L1 GUS enzymes, we manually docked pNPG into the active site of each GUS enzyme (Figs 4 and 5). Given the diversity of the active site loops within the GUS family, Loop 1 position and length likely influence the ability of GUS enzymes to process small glucuronide substrates. Indeed, the L1 GUS enzymes EcGUS, EcGUS, SaGUS, and CpGUS demonstrated the highest kₐₑₙ/Kₘ values compared to the non-L1 GUS enzymes (Table 2). The length (>15 amino acids) and position of Loop 1 in these enzymes appear to be suitable for stabilizing pNPG in their active sites and provide an explanation as to why these enzymes exhibited low Kₘ values (Table 1 and Fig. 4).

By contrast, the non-L1 GUS enzymes possess active site loops distinct in position or length compared to Loop 1. For example, mL1 BfGUS possesses a Mini Loop 1 (Fig. 5a). pNPG docking reveals that the Mini Loop 1 of BfGUS is too short to make productive contacts with pNPG (Fig. 5a). This observation suggests an explanation for why GUS enzymes possessing shorter loops between 10 and 15 residues, such as BfGUS, BoGUS, and PmGUS, poorly process pNPG. As observed in the crystal structure of mL2 PmGUS, a loop insert 41 residues in length occupies the active site and appears to clash with pNPG (Fig. 5b). As such, this loop insert may also explain why PmGUS displays a high Kₘ value (2.40 ± 0.07 mM) for pNPG (Table 1).

While BuGUS does not possess a shorter active site loop, the structure of this active site loop appears to explain why it does not process pNPG as efficiently as Loop 1 GUS enzymes. As reported in Pollet et al., the Loop 2 in BuGUS adopts an extended alpha helix structure (Fig. 5c). Therefore, in this state it is not capable of folding over the active site to make contacts with pNPG. In addition, NL BdGUS also lacks an active site loop; in contrast to BuGUS, however, it does possess a loop in its CBM domain that enters the BdGUS active site (Figs 3b and 5d). Despite this extra CBM loop, the absence of a loop ~15 residues in length that resides at the Loop 1 position may explain why BuGUS, BdGUS, and other non-L1 GUS enzymes exhibited higher Kₘ values for pNPG compared to EcGUS, EcGUS, SaGUS, and CpGUS.
Importantly, however, not all L1 GUS enzymes exhibited efficient $k_{cat}/K_m$ values. The three new L1 GUS enzymes were inefficient at processing $p$NPG, in part due to their high $K_m$ values. For $Rg$GUS, this may be explained by the alpha helix motif adopted by Loop 1 (Fig. 2c). Docking $p$NPG into the active site reveals that the alpha helix motif would sterically clash with $p$NPG (Fig. 4c). Therefore, the propensity for the loop in $Rg$GUS to form an alpha helix may explain its low catalytic efficiency. To determine whether other L1 GUS enzymes are capable of forming an alpha helix in the active site, we aligned the Loop 1 sequences (Fig. 4d). Sequence alignment revealed that $Fp$GUS retains five of the six amino acids, termed the “NFXAA motif” where “X” is a hydrophobic residue, that make up the alpha helix conformation in the $Rg$GUS loop, indicating that $Fp$GUS may also be capable of forming this secondary structure motif even though this loop is disordered in the structure of this enzyme presented here. This structural motif may aid in rationalizing the inability of these enzymes to process small glucuronide substrates. To determine whether crystal packing causes distinct L1 conformations, we analysed the loop-based symmetry contacts of each L1 shown in Fig. 4. In $Ec$GUS, $Sa$GUS, and $Rg$GUS, crystal contacts were observed, although fewer contacts were observed for $Rg$GUS compared to $Ec$GUS and $Sa$GUS. In contrast, no crystal contacts were observed within 25 Å of the $Ee$GUS L1 structure. These findings suggest that while crystal packing may dictate the L1 conformation in some GUS enzymes, it likely plays a minor role in the formation of the L1 alpha helix motif in $Rg$GUS.

Although $Lr$GUS does not possess the NFXAA motif, we hypothesized that the EDD motif, which places three anionic side chains into the active site, precludes the entry of neutral substrates and may explain the poor $p$NPG processing activity of $Lr$GUS. The EDD motif is unique to $Lr$GUS and was not present in the six other L1 GUS enzymes characterized in the study (Figs 2c and S3b). Site-directed mutagenesis of the EDD motif to the corresponding neutral polar residues QNN led to a complete loss of GUS activity (Fig. S13b), suggesting that this negatively charged patch is critical for small glucuronide processing by $Lr$GUS.

In general, the overall trends with small molecule glucuronide substrates were maintained when comparing $p$NPG and DCF-G processing activity. However, $Ec$GUS, the fastest and most efficient GUS at cleaving $p$NPG, was the slowest at processing DCF-G. Given that the aglycone is expected to primarily interact with the L1 in $Ec$GUS, we expect that the amino acid composition of L1 is responsible for this differential processing. Future studies will be carried out to evaluate how specific L1 residues affect $p$NPG and DCF-G processing.

Figure 4. Alignment of the Loop 1 regions in L1 GUS enzymes. (a) Overlay of $Ec$GUS (3LPG; dark green) with $Sa$GUS (4JKK; yellow), $Cp$GUS (4JKM; indigo), $Fp$GUS (cyan), and $Lr$GUS (magenta), with $p$NPG shown docked into the active site of $Ec$GUS. (b) Overlay of $Ec$GUS and $Ee$GUS (purple). The canonical Loop 1 is shown in dark purple. The additional active site proximal loop, termed “Ee Extra Loop”, is shown in magenta. Residues G152 through G156 were not previously built and are not shown. (c) Overlay of $Ec$GUS and $Rg$GUS (dark pink) (d) Sequence alignment of the Loop 1 regions from the seven L1 GUS enzymes characterized in this study. Amino acids that form the alpha helix in the Loop 1 of $Rg$GUS are boxed in red. Amino acids that correspond to the alpha helix position in the Loop 1 of $Rg$GUS are underlined.
UNC10201652 is more potent than Inhibitor 1 in vitro against all GUS enzymes. Here, we also present the IC50 values for Inhibitor 1 and UNC10201652 against a panel of GUS enzymes examined at two pH values. For the GUS enzymes inhibited, UNC10201652 demonstrated greater potency than Inhibitor 1 at both pH 6.5 and 7.5 (Table 2). For example, UNC10201652 was 19 times more potent against EcGUS at pH 7.5 than Inhibitor 1. The mechanism of action demonstrated by UNC10201652 may provide insight into its enhanced inhibitory activity. UNC10201652 displays unique substrate-dependent and slow-binding inhibition, in which it binds to the glucuronic acid (GlcA)-enzyme catalytic intermediate as a piperazine-linked glucuronide22. The resulting piperazine-linked glucuronide contains a positively charged piperazine amine and is predicted to form an electrostatic interaction with the catalytic acid/base glutamate in the active site (Fig. 6b)22. The presence of this ionic interaction likely aids in stabilizing the bound UNC10201652-GlcA conjugate in the active site. In contrast, only hydrogen bonds and hydrophobic interactions are present in the Inhibitor 1-bound complex (Fig. 6a). In addition, a conserved tyrosine in GUS enzymes (Y472 in EcGUS and CpGUS) forms pi-pi stacking interactions with the UNC10201652 aromatic scaffold, which may also aid in stabilizing the inhibitor-bound complex (Fig. 6b). This tyrosine is not expected to provide pi-pi stacking interactions with Inhibitor 1 (Fig. 6a).

The formation of the UNC10201652-GlcA conjugate within the GUS active site may also explain the pH dependency of UNC10201652, in which the inhibitory activity decreases with decreasing pH (Table 2). As the pH decreases, the catalytic glutamates are expected to be protonated, which would disrupt the ionic bond between a negatively charged glutamate and the positively charged piperazine amine.

Active site loop composition impacts L1 GUS inhibition. By comparing the IC50 values determined in this study, we found that the L1 Cluster GUS enzymes were not inhibited, or poorly inhibited, by the bacterial GUS inhibitors (Table 2). As stated above, the alpha helix formed in the Loop 1 of RgGUS and predicted to form in the Loop 1 of FpGUS may block the active site of this enzyme for productive binding to this substrate. This structural feature may also prevent Inhibitor 1 and UNC10201652 from accessing the active site pocket, resulting in the lack of inhibition observed for these L1 Cluster GUS enzymes.

Further, Inhibitor 1 and UNC10201652 displayed varying degrees of potency against the L1 GUS enzymes that were susceptible to inhibition (Table 2). The specific Loop 1 amino acid sequence likely explains the differences in inhibition observed for the L1 GUS enzymes (Fig. 4d). For example, Inhibitor 1 was found to be more potent against EcGUS than CpGUS (Table 2). Upon docking Inhibitor 1 into the active sites of these enzymes based on the previously determined structures of the Inhibitor 2- and Inhibitor 3-bound EcGUS complexes (PDB: 3LPF and 3LPG, respectively) and the UNC10201652-bound CpGUS complex, we observed that F365 present on the Loop 1 of the adjacent EcGUS monomer likely serves as a primarily contact with Inhibitor 1, as previously described (Fig. 6c)20. In CpGUS, a glycine is present at this position and may explain why Inhibitor 1 is
more effective at inhibiting EcGUS than CpGUS (Figs 4d and 6e). In contrast, UNC10201652 was determined to be more potent towards CpGUS than EcGUS. Again, the specific Loop 1 composition of both enzymes may provide an explanation for this observation. Upon docking UNC10201652 into the EcGUS active site, we found that F365 in the adjacent monomer may clash with the inhibitor scaffold, although the exact positioning of the loop and inhibitor is difficult to predict in the absence of a co-crystal structure (Fig. 6d). To test the role F365 plays in Inhibitor 1 and UNC10201652 potency, we determined the IC50 values for each inhibitor using EcGUS F365 variant protein. Inhibitor 1 and UNC10201652 were less potent toward the EcGUS F365 mutant than the WT (Fig. S14), suggesting that this residue aids in stabilizing both inhibitors and that the L1 in EcGUS adopts a conformation that accommodates UNC10201652. Given these results, the L1 in CpGUS may also adopt a conformation distinct from that displayed in Fig. 6e,f. Thus, the role specific L1 amino acids play in Inhibitor 1 and UNC10201652 binding, should be evaluated in future more expansive mutagenesis studies.

In addition, the L1 EcGUS was also only moderately inhibited by UNC10201652 and not inhibited by Inhibitor 1 (Table 2). While this may be explained in part by the specific Loop 1 composition of EcGUS, the presence of an additional Loop, named the “Ee Extra Loop”, distinct from the Loop 1 or Loop 2 position may also impede inhibitor binding in the active site (Figs 4b and S3a). To determine whether the Ee Extra Loop affects inhibitor potency, we deleted residues M149 to A159, which comprise the loop. Deletion of this region led to a significant loss of pNPG activity, with the mutant exhibiting 9% of the cleavage rate demonstrated by the WT (Fig. S13c). Circular dichroism (CD) analysis revealed that deletion of the Ee Extra Loop did not alter the overall fold of the enzyme (Fig. S15a). Thus, this additional loop appears to be important in small glucuronide processing.

**Figure 6.** Inhibitor 1 and UNC10201652 chemotypes within the EcGUS and CpGUS active sites. (a) Overlay of EcGUS and CpGUS containing the Inhibitor 1 chemotype docked into the active site. Loop 1 structures are not shown. (b) Overlay of EcGUS and CpGUS containing UNC10201652 docked into the active site. Loop 1 structures are not shown. (c) EcGUS loop 1 region with Inhibitor 1 docked into the active site. (d) EcGUS loop 1 region with UNC10201652 docked into the active site. (e) CpGUS loop 1 region with Inhibitor 1 docked into the active site. (f) CpGUS loop 1 region with UNC10201652 in the active site. Loop 1 structures are indicated by arrows. Grey loops are from the adjacent monomer.

**C-terminal domains affect substrate processing and GUS inhibition.** The crystal structure of NL BdGUS presented here, as well as the previously determined structures of non-L1 GUS enzymes, revealed the presence of additional C-terminal domains, including carbohydrate binding modules (CBMs) and domains of unknown function (DUFs). These additional domains may also provide additional rationale as to why non-L1 GUS enzymes, in general, process pNPG less efficiently than L1 GUS enzymes, which do not possess CBMs.
or DUFs (Figs 3a, S1, S16 and Table 1). The C-terminal domains cause non-L1 GUS enzymes to adopt more open active sites, as opposed to the "C-term-mediated" tetrameric state exhibited by L1 GUS enzymes that create smaller, more intimate active sites (Figs 2b and 3b). Such a configuration favours larger glucuronide-containing polysaccharide substrates over smaller drug glucuronides. In addition, CBMs, like that found in BdGUS, have been reported to mediate the binding and positioning of large carbohydrate substrates into the active site29, and their presence may indicate that larger polysaccharides are the native substrate of the GUS enzymes.

As noted above, BdGUS and BuGUS share highly similar tertiary and quaternary structures, but the catalytic efficiency of BdGUS was nearly 10-fold less than that of BuGUS (Fig. S4 and Table 1). Given that the main structural difference between these two enzymes is the presence of a CBM loop insert in BdGUS, the CBM loop may explain this difference in activity, as it may occlude a substrate like pNPG from being properly positioned in the active site. Such considerations address the binding of substrate to these enzymes (Km). It is also noteworthy that the kcat of the two enzymes also differ by 3-fold, something that we cannot explain using static structures and may involve distinctions in active site motion, as outlined elegantly for other enzyme systems30.

In addition, the presence or absence of C-terminal domains likely affects the binding of our GUS inhibitors. Here, we show that, with the exception of BdGUS, only GUS enzymes that do not contain a C-terminal domain are inhibited. The previously reported inhibitor-bound structures of EcGUS reveal that the selective GUS inhibitors make contacts with both the Loop 1 of the primary monomer as well as the Loop 1 of the adjacent monomer in its functional "C-term-mediated" tetrameric state (Fig. 7a)17,21. However, the presence of extra domains at the C-terminus of the GUS protein causes the enzyme to adopt either a "square" tetrameric state (e.g. BfGUS) or dimeric states (e.g. BuGUS and BdGUS) (Fig. 7b–d). These quaternary assemblies preclude the positioning of an additional loop near the active site of the primary monomer, resulting in fewer putative inhibitor contacts. Therefore, the lack of a "C-term-mediated" tetrameric state due to the presence of one or more C-terminal domains presents a plausible explanation as to why no inhibition was observed in the majority of non-L1 GUS enzymes. BdGUS, the exception to this observation, was slightly inhibited by UN10201652. However, the CBM loop in BdGUS may enter into the BdGUS active site and provide stabilizing contacts, enabling slight inhibition (Fig. 7d). To evaluate the role the CBM loop plays in UN10201652 inhibition, we deleted residues N737 to Y499 that form the CBM loop in BdGUS. While deletion of this region did not alter the stability of the BdGUS mutant, as assessed by CD-monitored thermal denaturation, it rendered the enzyme inactive with pNPG, preventing further inhibition studies (Figs S13a and S15d).
Concluding remarks. In summary, this work provides insight into the structural and functional diversity among GUS enzymes, specifically focusing on those of the L1 class, and advances our knowledge of the specific GUS enzymes that are capable of reactivating drug glucuronides in the gut. We have shown that not all L1 GUS enzymes efficiently process small glucuronide substrates and have provided several structural explanations to support these observations. However, those enzymes that process small substrate glucuronides well are inhibited by UNC10201652.

Methods

Uniprot protein accession codes. The Uniprot accession codes for the proteins examined here are: EcGUS (P05804), EcGUS (CAZ62Z2), SaGUS (Q8E0N2), CpGUS (Q8VN4V), LrGUS (C2I TS9), RgGUS (R2STA0), FpGUS (C7H4D2), BgGUS (Q5LIC7), BdGUS (C3R9X4), BbGUS (B0A078SUX9), BoGUS (A7LZ25), and PmGUS (A7AG62).

SSN construction. The sequence similarity network diagram of GUS enzyme sequences was generated using the online enzyme function initiative-enzyme similarity tool (EFEI-EST)\(^\text{31}\). The sequences obtained from the GUS rubric were used in combination with the EFEI-EST “fasta” tool to create a sequence with 282 nodes. Each node represents sequences bearing ≥90% sequence identity to each other. A BLAST E-value of 1 × 10\(^{-220}\) was employed.

Enzyme cloning. The GUS genes from Lactobacillus rhamnosus and Ruminococcus gravis were purchased from Bio Basic in the pUC57 vector. The genes were amplified by PCR and inserted into the ligation independent cloning vector (LIC) pLIC-His using the primers shown in Table S2. The pLIC-His vector contains a N-terminal 6× -histidine tag. For LrGUS and FpGUS crystallisation, an additional 36 amino acids and 33 amino acids were added to the C-termini of the LrGUS and FpGUS proteins, respectively, using the C-term primers (Table S2).

Site-directed mutagenesis. The EcGUS (−)EeLoop, EcGUS F365A, LrGUS EDD to QNN, and BdGUS (−)CBM Loop mutants were created using site-directed mutagenesis. Primers were synthesized by Integrated DNA Technologies and are shown in Table S2. The mutant plasmids were sequenced to confirm the mutations. The mutants were produced and purified using E. coli BL21 (DE3) Gold as described below.

CD analysis of GUS mutants. The protein stabilities of the WT and mutant GUS enzymes described above were determined using the Circular Dichroism method\(^\text{31}\). Enzyme (2.5 µM) in CD buffer containing 10 mM potassium phosphate (pH 7.4) and 100 mM potassium fluoride was loaded into a 1-mm pathlength cuvette. Using a Chirascan-plus instrument (Applied Photophysics Limited), spectra from 185 to 260 nm were recorded at 20 ± 1.0°C. Measurements were corrected for background signal using a CD buffer sample. The melting profile of the sample (2.5 µM) was monitored at 228, 220, 225, and 218 nm for EcGUS, EeGUS, LrGUS, and BdGUS, respectively, from 20°C to 94°C.

Enzyme expression and purification. All GUS enzymes were expressed and purified as previously described\(^\text{20}\). Expression and purification of LrGUS and RgGUS was identical to that previously described for EcGUS\(^\text{20}\). Briefly, LrGUS and RgGUS expression plasmids were transformed into BL21 DE3 Gold cells. Cells were grown in the presence of ampicillin in LB at 37°C until the OD\(_{600}\) reached 0.5, at which point the temperature was reduced to 18°C. At OD\(_{600}\) ~0.8, protein expression was induced by the addition of 0.1 mM isopropyl-1-thio-D-galactopyranoside (IPTG), and cells were incubated overnight. Cells were pelleted by centrifugation at 4500 × g for 20 min at 4°C. Cell pellets were resuspended in Buffer A (20 mM potassium phosphate pH 7.4, 50 mM imidazole, 500 mM NaCl), DNase, lysozyme, and a Roche complete EDTA free protease inhibitor tablet. Proteins contained 6x histidine tags and were purified by Ni-column affinity chromatography and eluted with Buffer B (20 mM potassium phosphate pH 7.4, 500 mM imidazole, 500 mM NaCl). After Ni-column chromatography, the proteins were subjected to size-column chromatography using Buffer C (20 mM HEPES pH 7.4, 50 mM NaCl). Protein eluents were then concentrated, flash frozen in liquid nitrogen, and stored at −80°C.

In vitro pNPG processing assay. The standard substrate p-nitrophenyl-β-D-glucuronide (pNPG) was purchased as a solid (Sigma Aldrich) and resuspended in water to a concentration of 100 mM. In vitro assays were conducted in 96-well, clear bottom assay plates (Costar, Tewksbury MA) at 37°C in a 50 µL total volume. Reactions consisted of 10 µL assay buffer (50 mM HEPES, 50 mM NaCl, various pH), 10 µL enzyme (various concentrations), and 30 µL pNPG (various concentrations) diluted in assay buffer. Protein formation was microsomalised on 410 nm using a PHERAstar Plus Microplate reader (BMG Labtech). To determine the optimal pH for SaGUS, CpGUS, LrGUS, and RgGUS, the above assay was conducted at various enzyme concentrations and 800 µM pNPG in the appropriate assay buffer where the pH ranged from 4.0 to 7.4. For assays at pH 6.0 or lower, reactions were quenched with 100 µL of 0.2 M sodium carbonate, and product formation was measured over time via absorbance at 410 nm. For reactions at pH 6.5 or above, reactions were not quenched. For CpGUS and RgGUS, pH 6.5 was selected as the optimal pH due to the ability to monitor product formation continuously at this pH. Upon determining the optimal pH for each enzyme, velocities were determined for multiple substrate and enzyme concentrations at each enzyme's optimal pH, and the Michaelis-Menten kinetics module in SigmaPlot was used to calculate K\(_{m}\), k\(_{cat}\), and catalytic efficiency.

RgGUS and BoGUS displayed complex substrate inhibition kinetics, and we were not able to fit these to established substrate inhibition models, including the uncompetitive substrate inhibition model, as determined in Equation 1, nor by the substrate inhibition models outlined in Lin et al. or Yoshino et al.\(^\text{26,27}\).
\[
\frac{v}{K_{\text{cat}}} + \frac{[S]}{K_m} \left(1 + \frac{[I]}{K_I}\right)
\]

Therefore, apparent \( k_{\text{cat}} \) and \( K_m \) values for \( \text{RgGUS} \) and \( \text{BoGUS} \) were estimated by plotting velocity versus pNPG concentrations at which no inhibition was observed.

**In vitro DCF-G processing assay.** Diclofenac acyl \( \beta \)-D-glucuronide (DCF-G) was purchased as a solid (LC Scientific Inc., Concord ON) and resuspended in DMSO to a concentration of 25 mM. In vitro assays were conducted at 37 °C in a 50 µL total volume. Reactions consisted of 10 µL assay buffer (50 mM HEPES, 50 mM NaCl, various pH), 10 µL enzyme (various concentrations), and 30 µL DCF-G (400 µM final) diluted in assay buffer. The pH of each reaction was chosen based on the optimal pH determined for each GUS with pNPG. Reactions were quenched at 0, 1, 2, 3, 4, and 5 min with 50 µL of 25% trichloroacetic acid (TCA). For pMngUS, reactions were quenched at 0, 10, 20, 30, 40, and 50 min. After centrifugation at 13,000×g for 10 min, the resultant supernatant was subjected to UPLC analysis. The concentration of DCF-G remaining at each time point was quantified on a Waters Acquity H-class liquid chromatograph system. Samples were separated on a Waters Acquity UPLC BEH C18 column (2.1 × 50 mm, 1.7 µm particle size) at 40 °C. The flow rate was 0.6 mL/min, and the injection volume was 3 µL. LC conditions were set at 100% water with 0.1% formic acid (A) ramped linearly over 9.8 mins to 95% acetonitrile with 0.1% formic acid (B) and held until 10.2 mins. At 10.21 mins the gradient was switched back to 100% A and allowed to re-equilibrate until 11.25 mins. DCF-G was monitored at 280 nm. The concentration of DCF-G was determined from a standard curve (0–500 µM DCF-G in assay buffer). Control reactions were performed in which enzyme was substituted with buffer. Background hydrolysis was not observed at each pH tested. Reactions were performed in triplicate for each enzyme.

**pNPG processing assay in faecal extracts.** All animal studies were approved by the University of North Carolina Institutional Animal Care and Use Committee (IACUC), in accordance with the Care and Use of Laboratory Animals guidelines set by the National Institutes of Health. Twelve-week old female C57/BL6J mice were individually housed in specific pathogen-free conditions with sterile ventilator cages containing corn bedding, with ad libitum access to chow and water. Prior to treatment, faecal pellets were collected from each mouse shortly by gentle abdominal palpation and snap frozen in sterile microfuge tubes. Animals received a single ulcerogenic dose of DCF (60 mg/kg) by intraperitoneal injection, as previously described.18 Twelve hours following DCF exposure, another set of faecal pellets were collected and stored as described above. To perform the assay, frozen faecal samples were rehydrated in 15 × assay buffer (weight/volume; 20 mM HEPES, 50 mM NaCl, pH 7.4, 1 × Complete® Protease inhibitor cocktail (Roche). Bacterial cells were lysed using a Tissuelyzer II (Qiagen) for 2 min at 30 Hertz. Homogenate was sonicated for 4 min, and then clarified by centrifugation for five minutes at 13,000×g. All experimental manipulation until this point occurred at 4 °C. 5 µL of faecal slurry supernatant was used to initiate the hydrolysis reaction of 1 mM pNPG resuspended in the same buffer. Parallel reactions containing only pNPG or only buffer/faecal slurry were used as negative controls; an aliquot of each sample was heated inactivated at 95 °C and used in the assay for further background establishment. Each sample was assayed using three technical replicates. The initial velocities of the resultant progress curves of the reaction were calculated in MATLAB by linear regression, and then normalized to the total faecal protein content calculated using a standard Bradford assay.

**In vitro inhibition assay.** In vitro inhibition of bacterial GUS enzymes by UNC10201652 was assessed as previously described.25. Reactions consisted of 5 µL of GUS (15 mM final for EcGUS, EeGUS, SaGUS, and CpGUS; 150 mM final for RgGUS, LrGUS, and BdGUS), 5 µL of inhibitor (various concentrations), 30 µL of pNPG (900 µM final), and 10 µL of assay buffer (25 mM NaCl, 25 mM HEPES, pH 6.5 or pH 7.5 final). Reactions were initiated by addition of pNPG and then incubated for 1 hour, after which the end point absorbance was determined. Due to the slow-binding nature of UNC10201652, the IC_{50} was determined as the inhibitor concentration that yielded a 50% reduction in the maximum absorbance of the uninhibited reaction, where percent inhibition was calculated as:

\[
\% \text{ inhibition} = \left[1 - \frac{A_{\text{exp}} - A_{\text{bg}}}{A_{\text{max}} - A_{\text{bg}}}\right] \times 100
\]

where \( A_{\text{exp}} \) is the end point absorbance at a particular inhibitor concentration, \( A_{\text{max}} \) is the absorbance of the uninhibited reaction, and \( A_{\text{bg}} \) is the background absorbance the assay. Percent inhibition values were subsequently plotted against the log of inhibitor concentration and fit with a four-parameter logistic function in SigmaPlot 13.0 to determine the IC_{50}.

In vitro inhibition of bacterial GUS enzymes by Inhibitor 1 was determined using the reaction conditions described above, but the IC_{50} was determined as the inhibitor concentration that yielded 50% reduction in the maximum initial velocity of the uninhibited reaction.

**Crystallization and structure determination.** Crystals of LrGUS, RgGUS, BdGUS and FpGUS were produced via the hanging-drop vapor diffusion method. LrGUS crystals were formed by incubation of 5 mg/mL LrGUS in 17% PEG3350, 0.4 M NaCl, and 0.1 Tris HCl pH 7.4 at 20°C. RgGUS crystals were formed by incubation of 16 mg/mL RgGUS in 1 M diammmonium hydrogen citrate and 0.05 M sodium acetate pH 4.5 at room temperature. BdGUS crystals were formed by incubation of 11.2 mg/mL BdGUS in 16% PEG3350 and 0.35 M sodium citrate at 20°C. FpGUS crystals were formed by incubation of 13 mg/mL FpGUS in 0.1 M bis-tris propane;
HCl, pH 7.0 and 0.4 M magnesium formate at 20 °C. For all crystals, 15% glycerol was used as the cryoprotectant. Diffraction data for all crystals were collected at APS beamline 23-ID-D and ID-B, and data were collected at 100 K. LrGUS, RgGUS, and FpGUS were solved via molecular replacement with E. coli GUS (PDB: 3LPG) in the software Phenix. BdGUS was solved via molecular replacement with Bacteroides uniformis GUS (PDB: SU16). Refinement was also performed in Phenix, with initial rounds of simulated annealing. Final coordinates and structure factors have been submitted to the RCSB and assigned accession codes 6ECA, 6EC6, 6ED2, and 6ED1 for the LrGUS, RgGUS, FpGUS, and BdGUS structures, respectively.

**SEC-MALS analysis of GUS enzymes.** RgGUS, LrGUS, FpGUS, and BdGUS were analysed on a Superdex 200 size exclusion column connected to an Agilent FPLC system. Wyatt DAWN HELEOS II multi-angle light scattering instrument and a Trex refractometer. The injection volume was 50 μL. RgGUS, LrGUS, and FpGUS were assessed at 3 mg/mL, and BdGUS was assessed at 10 mg/mL in 50 mM HEPES and 150 mM NaCl pH 7.4 buffer. A flow rate of 0.5 mL/min was used. Light scattering and refractive index data were collected and analysed using Wyatt ASTRA (Ver. 6.1) software. A dn/dc value of 0.185 was used for calculations, and a band-broadening correction was applied. Almost 100% of RgGUS, LrGUS, and FpGUS eluted in single peaks with weight-average molar masses of 291.5 kDa, 284.2 kDa, and 293.0 kDa, respectively, indicating that they form stable tetramers in solution. In contrast, BdGUS eluted in a single peak with a small trailing edge with a weight-average molar mass of 206.3 kDa, indicating that it is in dimer-tetramer equilibrium with dimer being the predominant species.

**Data Availability Statements**

The data sets generated during and/or analysed are either included in the published article or available from the corresponding author on reasonable request.

**References**

1. Balzola, F., Bernstein, C., Ho, G. T. & Lees, C. A human gut microbial gene catalogue established by metagenomic sequencing. *Commentary. Inflamm. Bowel Dis. Monit.* 11, 28 (2010).
2. Flint, H. J., Scott, K. P., Duncan, S. H., P. & Forano, E. Microbial degradation of complex carbohydrates in the gut. *Gut Microbes* 3, 289–306 (2012).
3. LeBlanc, J. G. et al. Bacteria as vitamin suppliers to their host: A gut microbiota perspective. *Curr. Opin. Biotechnol.* 24, 160–168 (2013).
4. Koh, A., De Vadder, F., Kovatcheva-Datchary, P. & Backhed, F. From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. *Cell* 165, 1332–1345 (2016).
5. O’Hara, A. M. & Shanahan, F. The gut flora as a forgotten organ. *EMBO Rep.* 7, 688–93 (2006).
6. Guinanee, C. M. & Cotter, P. D. Role of the gut microbiota in a healthy and chronic gastrointestinal disease: understanding a hidden metabolic organ. *Therap. Adv. Gastroenterol.* 6, 295–308 (2013).
7. Koppel, N., Rokkal, V. M. & Balskus, E. P. Chemical transformation of xenobiotics by the human gut microbiota. *Science.* 356, 1246–1257 (2017).
8. Almazroo, O. A., Miah, M. K. & Venkataramanan, R. Drug Metabolism in the Liver. *Clin. Liver Dis.* 21, 1–20 (2017).
9. Zamek-Gliszczynski, M. J., Hoffmaster, K. A., Nezasa, K. I., Tallman, M. N. & Brouwer, K. L. R. Integration of hepatic drug transporters and phase II metabolizing enzymes: Mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. *Eur. J. Pharmacol.* 27, 447–486 (2006).
10. Sousa, T. et al. The gastrointestinal microbiota as a site for the biotransformation of drugs. *Int. J. Pharm.* 163, 1–25 (2008).
11. Pellock, S. J. & Redinbo, M. R. Glucuronides in the Gut: Sugar-Driven Symbioses Between Microbe and Host. *J. Biol. Chem.* 292, 8569–8576 (2017).
12. Pommier, Y. Topoisomerase I inhibitors: Camptothecins and beyond. *Nat. Rev. Cancer* 6, 789–802 (2006).
13. Cani, M. P. et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. *Oncology* 67, 93–97 (2004).
14. Robert, J. & Rivory, L. Pharmacology of irinotecan. *Drugs Today (Barc).* 34, 777–803 (1998).
15. Takasuna, K. et al. Involvement of β-Glucuronidase in Intestinal Microflora in the Intestinal Toxicity of the Antitumor Camptothecin Derivative Irinotecan Hydrochloride (CPT-11) in Rats. *Cancer Res.* 56, 3752–3757 (1996).
16. Boelsterli, U. A., Redinbo, M. R. & Saitia, K. S. Multiple NSAID-induced hits injure the small intestine: Underlying mechanisms and novel strategies. *Toxicol. Sci.* 131, 654–667 (2013).
17. Wallace, B. D. et al. Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme. *Science.* 330, 831–835 (2010).
18. LoGuidice, A., Wallace, B. D., Bendel, L., Redinbo, M. R. & Boelsterli, U. A. Pharmacologic Targeting of Bacterial beta-Glucuronidase Alleviates Nonsteroidal Anti-Inflammatory Drug-Induced Enteropathy in Mice. *J. Pharmacol. Exp. Ther.* 341, 447–454 (2012).
19. Saitia, K. S. et al. Bacterial beta-gluconidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics. *Xenobiotica* 44, 28–35 (2014).
20. Pollet, R. M. et al. An Atlas of β-Glucuronidases in the Human Intestinal Microbiome. *Structure.* 25, 967–977 (2017).
21. Wallace, B. D. et al. Structure and Inhibition of Microbiome β-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity. *Chem. Biol.* 22, 1238–1249 (2015).
22. Pellock, S. J. et al. Gut Microbial β-Glucuronidase Inhibition via Catalytic Cycle Interception. *ACS Cent. Sci.* acscente.8b00239, https://doi.org/10.1021/acscentsci.8b00239 (2018).
23. Beaud, D., Talyliez, P. & Abu-Mondoloni, J. Genetic characterization of the beta-glucuronidase enzyme from a human intestinal bacterium Ruminococcus gravis. *Microbiology* 151, 2323–2330 (2005).
24. Atkinson, H. J., Morris, J. H., Ferrin, T. E. & Babbitt, P. C. Using sequence similarity networks for visualization of relationships across diverse protein superfamilies. *PLoS One* 4, (2009).
25. Schallus, T. et al. Malecin: A Novel Carbohydrate-binding Protein of the Endoplasmic Reticulum and a Candidate Player in the Early Steps of Protein N-Glycosylation. *J. Biol. Chem.* 19, 3404–3414 (2008).
26. Yoshino, M. & Murakami, K. Analysis of the substrate inhibition of complete and partial types. *Springerplus* 4 (2015).
27. Lin, Y. et al. Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. *Drug Metab. Dispos.* 29, 368–374 (2001).
28. Abuhelwa, A. Y., Foster, D. J. R. & Upton, R. N. A Quantitative Review and Meta-Models of the Variability and Factors Affecting Oral Drug Absorption—Part I: Gastrointestinal pH. *AAPS J.* 18, 1309–1321 (2016).
29. Boraston, A. B., Bolam, D. N., Gilbert, H. J. & Davies, G. J. Carbohydrate-binding modules: fine-tuning polysaccharide recognition. *Biochem. J.* 382, 769–781 (2004).
Acknowledgements

We thank Professor Temitope Keku, Department of Medicine, UNC School of Medicine, for information about adherent bacteria in patient biopsy samples. We also thank the University of North Carolina's Department of Chemistry Mass Spectrometry Core Laboratory, the University of North Carolina Macromolecular Interactions Facility, and Samantha Ervin for their experimental assistance. Research reported in this publication was supported in part with funding by the University of North Carolina's School of Medicine Office of Research and by the NIH grants CA098468 and CA207416. This work was also supported by the National Cancer Institute of the National Institutes of Health under award number P30CA016086. APB was supported by T32DK007737. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author Contributions

Conceptualization, M.R.R. and K.A.B.; Methodology, K.A.B. and S.J.P.; Investigation, K.A.B., S.J.P., A.P.B., B.T.T., L.W., M.C.S., M.M.B., A.P.C., A.T., D.A.E. and W.G.W.; Writing – Original Draft, K.A.B.; Writing – Review & Editing, M.R.R., K.A.B., A.P.B. and S.J.P.; Visualization, K.A.B.; Supervision, M.R.R.; Funding Acquisition, M.R.R.

Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-36069-w.

Competing Interests: M.R.R. is the scientific founder of Symberix, Inc., which is developing microbiome-targeted therapeutics.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019